We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Bio-Rad Introduces Anti-Evolocumab Antibodies for Use in Preclinical and Clinical Drug Development


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Bio-Rad Introduces Anti-Evolocumab Antibodies for Use in Preclinical and Clinical Drug Development"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha®) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. These sequence-defined, recombinant antibodies are suitable for developing highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for evolocumab and its biosimilars.


Evolocumab is a monoclonal antibody used for the treatment of hyperlipidemia, or elevated levels of cholesterol and other lipoproteins. It binds to PCSK9, preventing its interaction with low-density lipoprotein (LDL) receptors to reduce circulating cholesterol and other lipoproteins. The new range of five anti-evolocumab antibodies includes fully human IgG1 clones and TrailBlazer Antibodies with a SpyTag incorporated into their heavy chain, enabling site-directed conjugation or fast-switching to a bivalent Fab or a full-length Ig-like format within an hour. The antibodies can be used to develop PK bridging ELISAs to measure free drug or as a surrogate positive control or reference standard in an ADA assay.


“Bio-Rad’s range of ready-made and well-characterized anti-idiotypic antibodies keeps growing, offering researchers enhanced flexibility for the development of custom bioanalytical drug assays against a wide range of marketed biologic drugs,” said Hilary Latham, Bio-Rad Marketing Director, Life Science Group. “Generated under stringent quality control for batch-to-batch consistency, these antibodies can produce translatable and reproducible results, ensuring assay reliability.”


The recombinant antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display, along with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures a consistent and secure supply throughout the assay lifecycle.


The anti-evolocumab antibodies are approved for in vitro research purposes and for commercial in vitro testing services to support preclinical and clinical drug development.

  

Advertisement